Vyne Total Assets vs Common Stock Total Equity Analysis

VYNE Stock

USD 3.03 0.13 4.48%

Vyne Therapeutics financial indicator trend analysis is much more than just breaking down Vyne Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vyne Therapeutics is a good investment. Please check the relationship between Vyne Therapeutics Total Assets and its Common Stock Total Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Total Assets vs Common Stock Total Equity

Total Assets vs Common Stock Total Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vyne Therapeutics Total Assets account and Common Stock Total Equity. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Vyne Therapeutics' Total Assets and Common Stock Total Equity is 0.59. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Vyne Therapeutics, assuming nothing else is changed. The correlation between historical values of Vyne Therapeutics' Total Assets and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Vyne Therapeutics are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Total Assets i.e., Vyne Therapeutics' Total Assets and Common Stock Total Equity go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Assets

Total assets refers to the total amount of Vyne Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vyne Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most indicators from Vyne Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.At present, Vyne Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.23, whereas Issuance Of Capital Stock is forecasted to decline to about 347.7 K.

	2021	2022	2023	2024 (projected)
Gross Profit	11.4M	477K	424K	402.8K
Total Revenue	14.8M	477K	424K	402.8K

Gross Profit Total Revenue

Vyne Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Net Receivables	Short Term Investments
Total Assets		0.53	0.58	0.82	-0.02	-0.37	0.54	0.21	0.93	0.59	0.35	-0.52	0.38	0.38	-0.46	0.99	-0.23	0.68	-0.52	0.38	0.44	-0.74	0.3	0.34	0.14	0.64
Other Current Liab	0.53		0.9	0.56	0.06	-0.8	0.79	0.38	0.22	0.82	0.39	-0.63	0.79	0.77	-0.45	0.49	0.2	0.37	-0.64	0.73	0.81	-0.47	0.96	0.93	0.82	-0.24
Total Current Liabilities	0.58	0.9		0.55	0.29	-0.74	0.95	0.13	0.28	0.79	0.33	-0.5	0.81	0.73	-0.38	0.53	0.1	0.59	-0.8	0.76	0.75	-0.65	0.86	0.85	0.63	-0.14
Total Stockholder Equity	0.82	0.56	0.55		-0.23	-0.61	0.55	0.3	0.76	0.75	0.58	-0.89	0.46	0.65	-0.88	0.82	0.05	0.46	-0.62	0.28	0.68	-0.75	0.39	0.45	0.15	0.5
Net Debt	-0.02	0.06	0.29	-0.23		-0.15	0.19	-0.79	-0.15	0.06	0.11	0.31	0.24	0.13	0.36	-0.11	0.06	0.37	-0.32	0.24	0.12	-0.18	0.13	0.18	0.13	-0.05
Retained Earnings	-0.37	-0.8	-0.74	-0.61	-0.15		-0.65	-0.08	-0.14	-0.88	-0.79	0.75	-0.81	-0.99	0.63	-0.34	-0.39	-0.43	0.82	-0.44	-0.99	0.62	-0.84	-0.88	-0.6	0.11
Accounts Payable	0.54	0.79	0.95	0.55	0.19	-0.65		0.09	0.27	0.71	0.25	-0.49	0.76	0.64	-0.41	0.5	0.03	0.57	-0.73	0.59	0.64	-0.65	0.76	0.71	0.45	-0.1
Cash	0.21	0.38	0.13	0.3	-0.79	-0.08	0.09		0.17	0.17	-0.06	-0.36	-0.04	0.1	-0.31	0.27	-0.12	-0.28	0.09	0.36	0.13	0.15	0.31	0.26	0.42	-0.15
Cash And Short Term Investments	0.93	0.22	0.28	0.76	-0.15	-0.14	0.27	0.17		0.39	0.28	-0.42	0.15	0.17	-0.42	0.96	-0.27	0.61	-0.35	0.1	0.22	-0.67	-0.03	0.04	-0.17	0.83
Common Stock Total Equity	0.59	0.82	0.79	0.75	0.06	-0.88	0.71	0.17	0.39		0.56	-0.8	0.78	0.86	-0.72	0.57	0.35	0.47	-0.86	0.55	0.87	-0.75	0.77	0.84	0.51	-0.03
Common Stock Shares Outstanding	0.35	0.39	0.33	0.58	0.11	-0.79	0.25	-0.06	0.28	0.56		-0.62	0.4	0.82	-0.55	0.34	0.09	0.37	-0.58	0.06	0.82	-0.49	0.41	0.52	0.29	0.33
Non Current Liabilities Total	-0.52	-0.63	-0.5	-0.89	0.31	0.75	-0.49	-0.36	-0.42	-0.8	-0.62		-0.56	-0.78	0.96	-0.52	-0.34	-0.19	0.57	-0.23	-0.78	0.57	-0.55	-0.57	-0.31	-0.14
Other Current Assets	0.38	0.79	0.81	0.46	0.24	-0.81	0.76	-0.04	0.15	0.78	0.4	-0.56		0.77	-0.41	0.34	0.57	0.64	-0.77	0.39	0.78	-0.71	0.77	0.74	0.44	-0.18
Other Stockholder Equity	0.38	0.77	0.73	0.65	0.13	-0.99	0.64	0.1	0.17	0.86	0.82	-0.78	0.77		-0.68	0.35	0.35	0.42	-0.82	0.43	0.99	-0.62	0.81	0.86	0.58	-0.06
Total Liab	-0.46	-0.45	-0.38	-0.88	0.36	0.63	-0.41	-0.31	-0.42	-0.72	-0.55	0.96	-0.41	-0.68		-0.47	-0.3	-0.13	0.54	-0.14	-0.66	0.56	-0.37	-0.42	-0.12	-0.2
Total Current Assets	0.99	0.49	0.53	0.82	-0.11	-0.34	0.5	0.27	0.96	0.57	0.34	-0.52	0.34	0.35	-0.47		-0.23	0.66	-0.5	0.34	0.41	-0.73	0.25	0.3	0.09	0.66
Common Stock	-0.23	0.2	0.1	0.05	0.06	-0.39	0.03	-0.12	-0.27	0.35	0.09	-0.34	0.57	0.35	-0.3	-0.23		0.07	-0.33	0.0	0.33	-0.25	0.25	0.23	0.06	-0.37
Other Liab	0.68	0.37	0.59	0.46	0.37	-0.43	0.57	-0.28	0.61	0.47	0.37	-0.19	0.64	0.42	-0.13	0.66	0.07		-0.71	0.2	0.44	-0.87	0.26	0.29	-0.05	0.49
Net Tangible Assets	-0.52	-0.64	-0.8	-0.62	-0.32	0.82	-0.73	0.09	-0.35	-0.86	-0.58	0.57	-0.77	-0.82	0.54	-0.5	-0.33	-0.71		-0.54	-0.81	0.86	-0.64	-0.73	-0.33	-0.07
Property Plant And Equipment Net	0.38	0.73	0.76	0.28	0.24	-0.44	0.59	0.36	0.1	0.55	0.06	-0.23	0.39	0.43	-0.14	0.34	0.0	0.2	-0.54		0.46	-0.24	0.72	0.74	0.78	-0.32
Current Deferred Revenue	0.44	0.81	0.75	0.68	0.12	-0.99	0.64	0.13	0.22	0.87	0.82	-0.78	0.78	0.99	-0.66	0.41	0.33	0.44	-0.81	0.46		-0.63	0.83	0.87	0.61	-0.03
Non Current Assets Total	-0.74	-0.47	-0.65	-0.75	-0.18	0.62	-0.65	0.15	-0.67	-0.75	-0.49	0.57	-0.71	-0.62	0.56	-0.73	-0.25	-0.87	0.86	-0.24	-0.63		-0.35	-0.42	0.03	-0.45
Non Currrent Assets Other	0.3	0.96	0.86	0.39	0.13	-0.84	0.76	0.31	-0.03	0.77	0.41	-0.55	0.77	0.81	-0.37	0.25	0.25	0.26	-0.64	0.72	0.83	-0.35		0.97	0.88	-0.44
Other Assets	0.34	0.93	0.85	0.45	0.18	-0.88	0.71	0.26	0.04	0.84	0.52	-0.57	0.74	0.86	-0.42	0.3	0.23	0.29	-0.73	0.74	0.87	-0.42	0.97		0.87	-0.36
Net Receivables	0.14	0.82	0.63	0.15	0.13	-0.6	0.45	0.42	-0.17	0.51	0.29	-0.31	0.44	0.58	-0.12	0.09	0.06	-0.05	-0.33	0.78	0.61	0.03	0.88	0.87		-0.52
Short Term Investments	0.64	-0.24	-0.14	0.5	-0.05	0.11	-0.1	-0.15	0.83	-0.03	0.33	-0.14	-0.18	-0.06	-0.2	0.66	-0.37	0.49	-0.07	-0.32	-0.03	-0.45	-0.44	-0.36	-0.52

Click cells to compare fundamentals

Vyne Therapeutics Account Relationship Matchups

Vyne Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	79.2M	93.7M	67.0M	40.8M	97.7M	82.0M
Other Current Liab	485K	15.2M	11.2M	7.0M	5.6M	5.6M
Total Current Liabilities	10.7M	21.5M	18.4M	9.3M	7.5M	10.9M
Total Stockholder Equity	68.5M	37.5M	48.6M	31.2M	88.7M	93.2M
Net Debt	(30.1M)	(22.8M)	(41.9M)	(31.3M)	(30.4M)	(31.9M)
Retained Earnings	(184.3M)	(566.2M)	(639.5M)	(662.7M)	(691.3M)	(656.8M)
Accounts Payable	3.8M	4.8M	6.5M	2.4M	1.7M	3.3M
Cash	30.8M	57.6M	42.3M	30.9M	30.7M	36.6M
Cash And Short Term Investments	136.3M	76.9M	58.6M	42.3M	93.3M	70.3M
Common Stock Shares Outstanding	471.4K	1.8M	2.9M	3.2M	10.3M	10.8M
Liabilities And Stockholders Equity	79.2M	93.7M	67.0M	40.8M	97.7M	82.0M
Non Current Liabilities Total	34.3M	34.8M	6.9M	211K	1.4M	1.3M
Other Current Assets	1.4M	4.6M	6.1M	7.2M	2.7M	3.6M
Other Stockholder Equity	252.8M	603.7M	688.2M	692.3M	780.0M	819.0M
Total Liab	10.7M	56.2M	18.4M	9.6M	9.0M	8.5M
Total Current Assets	78.3M	87.3M	63.2M	38.3M	96.0M	78.4M
Other Liab	1.4M	1.1M	880K	769K	884.4K	997.5K
Net Tangible Assets	17.6M	37.5M	48.6M	31.2M	28.1M	48.6M
Property Plant And Equipment Net	769K	2.1M	354K	282K	207K	196.7K
Non Current Assets Total	842K	6.5M	3.9M	2.5M	1.7M	2.9M
Non Currrent Assets Other	73K	4.3M	3.5M	2.2M	1.5M	1.6M
Other Assets	744K	4.9M	3.5M	2.5M	2.9M	1.9M
Net Receivables	135K	15.8M	7.6M	5.2M	5.9M	5.3M
Short Term Investments	86.7M	46.2M	1.0M	0.0	62.6M	65.8M
Property Plant And Equipment Gross	98K	2.1M	354K	0.0	207K	412.2K
Accumulated Other Comprehensive Income	(51K)	(96K)	24K	26K	29.9K	31.4K
Non Current Liabilities Other	22K	7K	457K	1.3M	1.5M	1.6M
Property Plant Equipment	2.2M	4.6M	2.1M	354K	318.6K	302.7K
Net Invested Capital	68.5M	70.7M	48.6M	31.2M	88.7M	59.9M
Net Working Capital	67.7M	65.8M	44.8M	28.9M	88.4M	55.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:

How To Invest In Vyne

Details

Is Vyne Stock a good investment?

Details

What is Vyne Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

1.72

Revenue Per Share

0.016

Quarterly Revenue Growth

0.467

Return On Assets

(0.35)

Return On Equity

(0.60)

The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vyne Total Assets vs Common Stock Total Equity Analysis

Total Assets vs Common Stock Total Equity

Total Assets vs Common Stock Total Equity Correlation Analysis

Correlation Coefficient

Total Assets

Common Stock Total Equity

Vyne Therapeutics fundamental ratios Correlations

Vyne Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vyne Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Current Deferred Revenue	+ 0.99	Other Stockholder Equity
Other Assets	+ 0.97	Non Currrent Assets Other
Non Currrent Assets Other	+ 0.96	Other Current Liab
Total Current Assets	+ 0.96	Cash And Short Term Investments
Total Liab	+ 0.96	Non Current Liabilities Total

Current Deferred Revenue	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Non Current Liabilities Total	- 0.89	Total Stockholder Equity
Other Assets	- 0.88	Retained Earnings
Common Stock Total Equity	- 0.88	Retained Earnings
Total Liab	- 0.88	Total Stockholder Equity